Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 429

1.

Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.

van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM.

Eur Urol. 2007 Aug;52(2):455-63. Epub 2006 Nov 17.

PMID:
17134822
2.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
3.

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.

Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, Zhang Z, He Q, Chang C.

Ann Hematol. 2011 Jun;90(6):643-53. doi: 10.1007/s00277-010-1128-5. Epub 2010 Dec 2.

PMID:
21125401
4.

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.

Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R, Otte AP.

Br J Haematol. 2001 Mar;112(4):950-8.

PMID:
11298590
5.
6.

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.

Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H.

Cancer. 2010 Jun 15;116(12):3015-24. doi: 10.1002/cncr.25128.

7.

Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.

Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H, Packeisen J, Sewalt RA, Otte AP, van Diest PJ.

Neoplasia. 2003 Nov-Dec;5(6):481-8.

8.

Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.

Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA.

Cancer Biol Ther. 2007 Sep;6(9):1403-12.

PMID:
18637271
9.

Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.

Sánchez-Beato M, Sánchez E, González-Carreró J, Morente M, Díez A, Sánchez-Verde L, Martín MC, Cigudosa JC, Vidal M, Piris MA.

Mod Pathol. 2006 May;19(5):684-94.

10.

The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.

Wolters T, Vissers KJ, Bangma CH, Schröder FH, van Leenders GJ.

BJU Int. 2010 Jul;106(2):280-6. doi: 10.1111/j.1464-410X.2009.08998.x. Epub 2009 Nov 3.

11.

Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes.

Sewalt RG, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satijn DP, Hendrix T, van Driel R, Otte AP.

Mol Cell Biol. 1998 Jun;18(6):3586-95.

12.

A panel of monoclonal antibodies against human polycomb group proteins.

Hamer KM, Sewalt RG, den Blaauwen JL, Hendrix T, Satijn DP, Otte AP.

Hybrid Hybridomics. 2002 Aug;21(4):245-52.

PMID:
12193277
13.

The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.

Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T, Nakanuma Y.

Lab Invest. 2008 Aug;88(8):873-82. doi: 10.1038/labinvest.2008.52. Epub 2008 Jun 30.

14.

Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.

Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A, Yokosuka O.

Hum Pathol. 2009 Sep;40(9):1304-11. doi: 10.1016/j.humpath.2009.01.017. Epub 2009 Apr 22.

PMID:
19386347
15.

Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.

Hernández-Muñoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M.

Mol Cell Biol. 2005 Dec;25(24):11047-58.

16.

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.

Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen M.

Breast Cancer Res. 2008;10(6):R109. doi: 10.1186/bcr2214. Epub 2008 Dec 19.

17.

FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.

Du J, Li L, Ou Z, Kong C, Zhang Y, Dong Z, Zhu S, Jiang H, Shao Z, Huang B, Lu J.

Breast Cancer Res Treat. 2012 Jan;131(1):65-73. doi: 10.1007/s10549-011-1396-3. Epub 2011 Apr 5. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(3):609-10.

PMID:
21465172
18.

Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance.

Hinz S, Kempkensteffen C, Christoph F, Krause H, Schrader M, Schostak M, Miller K, Weikert S.

Tumour Biol. 2008;29(5):323-9. doi: 10.1159/000170879. Epub 2008 Nov 5.

PMID:
18984978
19.

The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.

Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP.

Cell Cycle. 2010 Jul 1;9(13):2663-73.

20.

Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.

Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A.

Int J Oncol. 2011 Feb;38(2):345-53. doi: 10.3892/ijo.2010.868. Epub 2010 Dec 9.

PMID:
21165554

Supplemental Content

Support Center